Pyrido[3,4-b]pyrazine GPR6 Modulators for Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and psychiatric disorders, such as Parkinson's disease, lack effective alternatives to dopamine-mediated activation, particularly in modulating G-Protein-Coupled Receptor 6 (GPR6) signaling, which is opposed to D2 receptor signaling in the central nervous system.
Innovation Solution
Development of specific compounds that act as modulators of GPR6, antagonizing or inverse agonizing the Gs-coupled receptor to decrease cAMP levels in medium spiny neurons, offering a functional alternative to dopamine activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current treatments for neurological disorders are used, then dopamine-mediated activation is maintained, but effective alternatives to modulate GPR6 signaling are lacking
Solution Approach 1:
The patent segments the treatment approach by developing specific compounds that selectively modulate GPR6 signaling independently from dopamine-mediated pathways. The compounds of formula I are designed to specifically target GPR6 receptors in medium spiny neurons, separating the modulation of GPR6 from the broader dopamine receptor system, thereby providing a targeted therapeutic strategy for neurological disorders
Solution Approach 2:
The patent introduces compounds of formula I as intermediary substances that mediate the modulation of GPR6 signaling. These compounds act as intermediaries between the therapeutic goal (modulating GPR6) and the biological system, providing a functional alternative to direct dopamine activation by interfering with GPR6-mediated cAMP signaling in medium spiny neurons
2Adaptability or versatility
If GPR6 signaling is modulated to decrease cAMP levels, then a functional alternative to dopamine activation is provided, but the complexity of compound structure increases
Solution Approach 1:
The patent applies parameter changes by systematically varying structural parameters of the compounds (substituents R1-R8, ring structures, linker groups) to optimize both the biological activity (functional alternative mechanism) and the structural characteristics. The general formula I framework allows for parameter optimization while maintaining the core pharmacophore required for GPR6 modulation
Solution Approach 2:
The compounds of formula I are designed with universal applicability for treating multiple neurological and psychiatric disorders by modulating GPR6 signaling. The core molecular structure provides a multi-functional platform that can address various conditions (Parkinson's disease, levodopa-induced dyskinesias, Huntington's disease, etc.) through the common mechanism of decreasing cAMP levels in medium spiny neurons via GPR6 antagonism or inverse agonism
Data Source
AI summary
The present invention provides compounds of formula I:which are useful as modulators of GPR6, pharmaceutical compositions thereof, methods for treatment of conditions associated with GPR6, processes for making the compounds and intermediates thereof.